ArticleBioMed research international2026
Evaluation of the Probiotic Potential of Lactobacillus acidophilus Strain JB2CON.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the Probiotic Potential of Lactobacillus acidophilus Strain JB2CON.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProbiotics have attracted much attention recently because of their potential health benefits and aim at correcting the imbalance of gut microbiota. Dairy fermented foods play an important role as a probiotic carrier, and fermented dairy products like dahi are well known for their ability to maintain the viability of bacteria and their acceptance by consumers. Nevertheless, the production of low-cost, locally manufactured probiotic products that possess antimicrobial activity against food pathogens is relatively scarce. The principal goal of this current study was to isolate a new potential probiotic strain to prepare contamination-free probiotic dahi in a dosage form with a desired shelf life.
methodTo achieve our target, firstly, probiotic dahi was prepared by a probiotic strain, Lactobacillus acidophilus JB2CON (OM909067) (identified by 16S sequencing) isolated from natural dahi in Dhaka, Bangladesh. Probiotic potential was assessed by transmission electron microscopy, acid and bile tolerance, hemolytic activity, antibiotic sensitivity, and antagonistic activity against pathogens, while sensory acceptance of the probiotic dahi was evaluated by 16 participants using a 9-point hedonic scale.
resultsThe isolate exhibited five probiotic features by in vitro test and had an antagonistic effect against four different bacterial pathogens and Candida albicans. More interestingly, it inhibited Escherichia coli (diameter of zone of inhibition = 15.75 ± 0.35) the most. In the time-kill analysis method, E. coli was killed within 5.50 h of fermentation. In the antibiotic sensitivity test, the isolated bacterial species exhibited clear inhibition, with ampicillin producing the largest zone (69.33 ± 11.06 mm), followed by tylosin (67.33 ± 6.43 mm). In the acid tolerance test, the probiotic count decreased by ~3.3 log units after 24 h, while bile salt exposure (0.025% and 0.5% oxgall) reduced viable counts in a concentration-dependent manner. The probiotic dahi prepared in this study was rated as "moderately liked" by 16 participants using a 9-point hedonic scale. Stability testing identified 14 days as the optimal shelf life, with increased probiotic counts and no adverse effect of minor pH changes on dahi taste.
conclusionThe most significant impact of this research is that the probiotic dahi of our experiment might be used as a cheap option for preventing pathogenic E. coli-related foodborne diseases worldwide, especially in underdeveloped countries like Bangladesh.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.